Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

Circulation

Volumn 100, Issue 12, 1999, Pages 1311-1315

  Cooper, Howard A ^a,b   Dries, Daniel L ^a,b   Davis, C E ^c   Shen, Yuan Li ^c   Domanski, Michael J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c IL   (United States)

Author keywords

Arrhythmia; Diuretics; Heart failure; Potassium

Indexed keywords

DIURETIC AGENT; ELECTROLYTE; ENALAPRIL; POTASSIUM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROLYTE DISTURBANCE; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK;

EID: 0033592418     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.12.1311     Document Type: Article

References (29)

1. Schappert SM, ed. National Ambulatory Medical Care Survey: 1991 Summary. Vital Health Star 13. 1994;13(116):78-80.
2. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
4. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
5. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med. 1995;122:223-226.
6. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-15.
7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
8. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
9. Bigger JT Jr. Diuretic therapy, hypertension, and cardiac arrest. N Engl J Med. 1994;330:1899-1900. Editorial.
10. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Mean J. 1994;128:564-574.
11. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA. 1997;277:739-745.
12. The SOLVD Investigators. Studies Of Left Ventricular Dysfunction (SOLVD): rationale, design, and methods: 2 trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
14. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
16. Hollifield JW. Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. Am J Med. 1984;77:28-32.
17. Lim P, Jacob E. Magnesium deficiency in patients on long-term diuretic therapy for heart failure. BMJ. 1972;3:620-622.
18. Carlsen JE, Kober L, Torp-Pederson C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990;300:975-978.
19. Seigel D, Hulley SB, Black DM, Cheitlin MD, Sebastian A, Seeley DG, Hearst N, Fine R. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA. 1992;267:1083-1089.
20. Papademetriou V, Fletcher RD, Khatri IM, Preis ED. Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias. Am J Cardiol. 1983;52:1017-1022.
21. Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J. 1979;97:12-18.
22. Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes in hypokalemic patients before and after correction of the hypokalemia. Acta Med Scand. 1978;204:375-379.
23. Abraham AS, Rosenman D, Meshulam D, Zion M, Eylath U. Serum, lymphocyte, and erythrocyte potassium, magnesium, and calcium concentrations and their relation to tachyarrhythmias in patients with acute myocardial infarction. Am J Med. 1986;81:983-988.
24. Bigger JT Jr. Antiarrhythmic treatment: an overview. Am J Cardiol. 1984;53:8B-16B.
25. Bigger JT Jr. Identification of patients at high risk for sudden cardiac death. Am J Cardiol. 1984;54:3D-5D.
26. Bergler-Klein J, Sochor H, Pouler H, Porenta G, Glogar D, for the Xamoterol in Severe Heart Failure Study Group. Safety of concomitant potassium-sparing diuretics in angiotensin-converting enzyme inhibitor therapy in severe congestive heart failure. J Cardiovasc Pharmacol. 1994;24:194-198.
27. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
28. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
29. Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J. 1995;16(suppl N): 107-110.